Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2533342 | 0.96 | MAPT (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL719493 | 0.96 | MAPT (0.43) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL170202 | 0.95 | MEN1 (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3414861 | 0.95 | MEN1 (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7709080 | 0.92 | MEN1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.92 | MEN1 (0.49) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.92 | MEN1 (0.49) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL14246467 | 0.91 | MEN1 (0.39) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL168983 | 0.91 | MEN1 (0.48) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104043 | 0.91 | MEN1 (0.48) | MAPTMEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057815-A | Novel 6-6 bicyclic aromatic ring substituted nucleosides as PRMT5 inhibitors | 詹森药业有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-107922413-B | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogs as PRMT5 inhibitors | 詹森药业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-105980378-A | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-10-02 | — | — | US | disclosed |
| US-20060160865-A1 | Pyridinyl carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636205-A1 | PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111031-A1 | PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| US-6153641-A | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | KIT, TYRO3, LCK | MAPT 4143/4885MEN1 4312/4885KMT2A 941/4885 |
| US-20060160865-A1 | Pyridinyl carbamates | LIPE, PNLIP, LPL | MAPT 3814/4885MEN1 1310/4885KMT2A 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.